Premium
S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up
Author(s) -
Lang Berenice M.,
Balermpas Panagiotis,
Bauer Andrea,
Blum Andreas,
Brölsch G. Felix,
Dirschka Thomas,
Follmann Markus,
Frank Jorge,
Frerich Bernhard,
Fritz Klaus,
Hauschild Axel,
Heindl Ludwig M.,
Howaldt HansPeter,
Ihrler Stephan,
Kakkassery Vinodh,
Klumpp Bernhard,
KrauseBergmann Albrecht,
Löser Christoph,
Meissner Markus,
Sachse Michael M.,
Schlaak Max,
Schön Michael P.,
Tischendorf Lutz,
Tronnier Michael,
Vordermark Dirk,
Welzel Julia,
Weichenthal Michael,
Wiegand Susanne,
Kaufmann Roland,
Grabbe Stephan
Publication year - 2019
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.13755
Subject(s) - basal cell carcinoma , medicine , incidence (geometry) , risk stratification , medline , basal cell , intensive care medicine , dermatology , pathology , biology , biochemistry , physics , optics
Summary Basal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.